Purpose: This study wax designed to examine changes in peripheral plasma substance-P and -K levels, their 
INTRODUCTION
Substance-P (SP) is a neuropeptide consisting of 11 amino acids. It belongs to the family of tachykinins. This neurohormone is widely distributed through the brain, gastrointestinal tract, and urogenital tract and exhibits a wide variety of biological effects, including regulation of blood flow, smooth-muscle activity, transmission of pain signals, and brain distribution consistent with a possible modulating action on regulation and release of gonadotropins from the pituitary and gonadal-hypothalamic feedback (1) (2) (3) (4) .
The structural characteristics, biological activity, and localization of substance-K (SK) are similar to those of SP. Although the decapeptide SK shares many of the biological effects of SP, there is very little information about the possible neuroendocrine role of SK (5, 6) .
Immunocytochemicai studies indicate that tachykinin-containing neurons and fiber systems are coexistent with the luteinizing hormone-releasing hormone (LH-RH) neural pathways in the hypothalamus (7) . Tachykinins may play a role in the control of hypothalamic LH-RH and pituitary LH secretion (8) (9) (10) (11) . SP was able to inhibit gonadotropin-releasing hormone (GnRH)-stimulated LH secretion from cultured human pituitary cells in a dose-dependent manner (4) .
The possibility that brain SP may have a physiologic role in gonadotropin release was documented by Kerdelhue et al. (12) , who observed that intracerebroventricular administration of SP to female rats completely blocked the preovulatory surge of LH and folliclestimulating hormone (FSH).
Measuring SP concentration in the median eminence, the arcuate, and the medial preoptic nucleus in the female rat, significant estrous cycle-related fluctuations were recorded for SP. The concentration of SP was highest throughout the day of proestrus, compared to 3 other days of the estrous cycle (13) . A similar observation was recently made at the blood level (14) . In in vivo experiments in rats, a single subcutaneous injection of SP on the day of proestrus significantly decreased the preovulatory surge of LH. The stimulatory effect of progesterone (P4) on GnRH-induced LH release was reduced by treatment with SP in vitro, 547 1058-0468/98/1000-0547$15.00/0 C 1998 Plenum Publishing Corporation KEY WORDS: substance-P; substance-K; gonadotropin surge. using the anterior lobe of the pituitary gland placed in a perifusion chamber (15) , In ovariectomized monkeys treated with estradiol benzoate, there is a sequential increase in the in vitro hypothalamic secretion of B-endorphin, GnRH, and SP, in that order. Furthermore, exposure to P 4 at 48 hr post-estradiol benzoate led to an acute augmentation of SP release (16) (17) (18) . Furthermore, SP inhibits LH release in the ovariectomized monkeys.
In the present study, we sought to determine changes in plasma concentration of SP and SK in the human and their correlation with the midcycle gonadotropin surge, as well as estradiol (E 2 ) and P 4 levels, to elucidate the possible mechanisms of these neuropeptides in regulation of normal reproductive cycles.
MATERIALS AND METHODS
Fourteen healthy women between 26 and 35 years of age were studied. Each had regular ovulatory reproductive cycles, and none used hormonal medication for 3 months before the study. All women were of normal weight and height. The project was approved by the Institutional Review Board of the Eastern Virginia Medical School, and informed consent was obtained from each woman. The duration of the study was 4-14 days, which began as early as day 4 of the menstrual cycle.
Following a brief office visit, daily pelvic ultrasound was performed for assessment of follicular growth and documentation of follicular rupture to confirm ovulation during each day of participation. Two test tubes of blood were drawn each day. A 15-ml blood serum sample was collected for FSH, LH, E 2 -17B, and P 4 . An additional 10 ml of blood was collected in ethylenediaminetetracelic acid-containing tubes placed on crushed ice and spun for 10 min at 4°C at 1500g. The plasma samples were stored at -2°C until assayed for plasma SP and SK. E 2 , FSH, and LH determinations were performed by microparticle enzyme immunoassays using the IMX analyzer (Abbott Laboratories, Abbott Park, IL). Progesterone determinations were made using a commercially available radioimmunoassay kit (Pantex, Santa Monica, CA).
SP and SK determinations were performed by specific radioimmunoassays following Sep-Pak extractions (Sep-Pak columns; Waters Associates, Milford, MA), filled with a nonpolar stationary phase. SepPak C18 was used for the preparation of samples for radioimmunoassays of SP and SK. Briefly, the cartridges were prepared by successive washings with 5 ml of ethanol, 5 ml of 8 M urea, and 10 ml of H 2 O before the samples were introduced to the column. The columns were then washed with 10 ml of H 2 O and 10 ml of 4% acetic acid. The retained peptides were eluted with 5 ml of a mixture of ethanol (90%) and acetic acid (4%), after overnight rotoevaporation of the eluted solution in a Savant Speed Vac Concentrator System (Savant Instrument, Inc., Farmingdale, NY). The residuum was reconstituted in radioimmunoassay buffer and SP and SK measured (19) .
Cycle days were standardized to LH surge on day 14 of reproductive cycles. Repeated-measures analysis of variance was used to test for trends over cycle days for each variable. To determine whether there was a relationship between changes in SP or SK and changes in E 2 , LH, FSH, or P 4 over standardized cycle days, each subject's SP/SK data were plotted along with E 2 , LH, FSH, or P 4 data from day 6 to day 17. Data at days 4, 5, 18, 19, and 20 were sparse and were omitted from the analyses. Figure 1 is a composite pattern of mean (± standard error of the man) serum concentration of E 2 , LH, FSH, P 4 , SP, and SK of 14 normal cycling women, standardized to peak LH at day 14.
RESULTS
There were significant trends (P < 0.001 for all) for E 2 , LH, FSH, and P 4 . Estradiol peaked on day 13, LH and FSH peaked on day 14, and P 4 began an exponential increase on approximately day 13. There was no significant trend for SP (P = 0.8391) or for SK (P = 0.3205). The trend for both was virtually a horizontal line. The mean of SP over days 6-17 was 6.24 pg/ml, and the mean of SK over days 6-17 was 0.72 pg/ml. Individual changes from day to day can be viewed as simply random fluctuations about these means and are not related to changes in E 2 , FSH, LH, or P 4 ( Fig. 1) .
DISCUSSION
The classic theory behind the initiation of the midcycle surge of LH is that when ovarian E 2 secretion reaches critical levels, it elicits positive feedback on the hypothalamus and pituitary, which results in increased output of GnRH and LH. It is established that the sensitivity of the pituitary to GnRH varies during the menstrual cycle in synchrony with changes in circulating E 2 levels (20) . E 2 has opposite effects on SP mRNA levels in the hypothalamus compared with the anterior The regulation of pituitary gonadotropin secretion in mammals is believed to involve a balance between GnRH input from the hypothalamus and feedback regulation from the gonads. Both LH and FSH are subject to the negative feedback of ovarian steroids. Changes in the frequency of the GnRH pulse from the hypothalamus can account for some of the changes in the LH:FSH ratio (21) . The action of GnRH is modulated by several factors at the pituitary level, thereby resulting in differential production and secretion of the LH and FSH, and has self-potentiating effects on the gonadotropins (22) . Estradiol enhances the self-priming effects of GnRH on the pituitary and potentates pituitary responsiveness to GnRH by increasing the number of GnRH receptors through direct stimulation of protein synthesis required for receptor formation (23) . At the same time, E 2 decreases the number of SP receptors at the pituitary level (2) . FSH and LH secretions were stimulated after immunoneutralization of endogenous SP in the cyclic rat, indicating physiologically significant inhibitory effect on LH release (24) . SP inhibits GnRH-stimulated LH and FSH release from rat anterior pituitary cell in primary culture (24) . SP apparently does not act through an inhibitory effect on hypothalamic GnRH release but, rather, on GnRHinduced LH release directly at the anterior pituitary level. Secretion of LH at midcycle is of physiological significance because it is responsible for the completion of oocyte maturation and ovulation and for conversion of the preovulatory follicle into a corpus luteum (25) . Progesterone stimulates SP release from the hypothalamus at the appropriate time to terminate GnRH stimulation of LH surge (16) . Therefore, SP may modulate initiation and termination of the midcycle LH surge (4). Secretion of FSH and LH is controlled through release of GnRH from the hypothalamus into the pituitary portal circulation (26) . There is a poor correlation between peripheral LH-RH and LH activity. This may be because of dilution of spillover hypothalami LH-RH in the peripheral circulation (27) . SP within the hypothalamus or anterior pituitary may function as a local or paracrine substance to facilitate synaptic regulation of GnRH release or may be released into hypophyseal portal circulation to modulate LH release.
In the present work, blood samples from one time point per day (morning) failed to provide evidence for a human menstrual cycle-related fluctuation in blood SP and SK, contrary to what was seen during the estrous cycle in the female rat. However, in the rat the estrous cycle variation of SP and SK was evidenced using the sampling of five time points per day. Nevertheless, there is a point that must be emphasized: there is two times more SP than SK in the cycling woman during the menstrual cycle, contrary to the situation in the cycling rat, where equivalent concentrations of SP and SK were observed. Furthermore, SP and SK concentrations stay almost in parallel in the human but evolved in an opposite way throughout the rat estrous cycle. This could represent a major difference in the synthesis and release of SP and SK between the human and the rat and emphasizes the major role of SP in both species.
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